News | May 13, 2013

Sliding Scale Hydration Washes Out Contrast-Induced Kidney Complications

Results of POSEIDON suggest novel hydration regimen reduces renal complications in patients undergoing image-guided cardiovascular procedures

May 13, 2013 — A new method of dynamic, personalized intravenous hydration significantly reduces the percentage of contrast-induced kidney injury from image-guided cardiovascular procedures, according to the results of the POSEIDON clinical trial presented as a late-breaking clinical trial at the SCAI 2013 Scientific Sessions.

Interventional cardiologists are able to perform minimally invasive procedures, such as angioplasty and stenting, because of imaging technologies that allow them to see inside the heart and blood vessels without open surgery. Use of iodine-based angiography imaging contrast media is generally safe, but for some patients with drug sensitivities or compromised kidney function, a complication called contrast-induced nephropathy can result. To prevent this complication, most institutions deliver intravenous saline hydration, which until now has not been tailored to the individual patient. The POSEIDON trial compared this standard hydration method with a new model for intravenous hydration that measures a patient’s blood pressure to determine how much hydration to provide.                                                                                          

“Hydration is the cornerstone for preventing damage to the kidneys, yet fundamental gaps in our knowledge remain,” said Somjot S. Brar, M.D., MPH, interventional cardiologist, vascular specialist and vice chair of area research at Kaiser Permanente Los Angeles Medical Center in Los Angeles, Calif. “For example, there is little evidence to help guide rate and duration of hydration. The results from this trial provide a concrete framework for performing hydration.”

POSEIDON is the first randomized clinical trial to study personalized hydration based on an aspect of the patient’s own blood pressure. The trial enrolled 396 patients with a mean age of 71 and stable renal insufficiency who were undergoing coronary angiography or percutaneous coronary intervention. Prior to their procedure, patients were divided into two groups, either receiving standard hydration or hydration calculated based on a measurement of intra-cardiac pressure called left ventricular end-diastolic pressure (LVEDP). Both groups received hydration via saline IV throughout the procedure and for four hours afterward.

Approximately 7 percent of patients in the experimental group experienced contrast-induced nephropathy, versus approximately 16 percent of patients treated with standard hydration.

The cumulative rate of major adverse events, tracked over six months and registered as a composite of dialysis and other renal therapy, heart attack and death, was 68 percent lower in the group that received personalized hydration.

“Hemodynamically guided hydration significantly reduced the rates of both contrast-induced nephropathy and major adverse events,” said Brar. “This is the first contrast-induced nephropathy prevention study to show a major reduction in important clinical events. We believe these findings should impact clinical practice and will likely have important implications for patients at risk of contrast-induced nephropathy undergoing cardiac catheterization.”

To watch a video of this data presentation from the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting.

Brar reports no conflicts of interest.

For more information: www.scai.org

Related Content

Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Siemens Healthineers Announces First U.S. Install of Artis Pheno Angiography System
News | Angiography | July 05, 2017
July 5, 2017 — Michigan Medicine recently became the first healthcare institution in the United States to install the
RaySafe Introduces Pro-Slit Camera for Accurate Focal Spot Measurement
Technology | Digital Radiography (DR) | June 27, 2017
Unfors RaySafe recently introduced the RaySafe Pro-Slit Phantom and the RaySafe Pro-Stand.
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Overlay Init